Method of quantifying peptide-derivative libraries using phage display
11493503 · 2022-11-08
Assignee
Inventors
Cpc classification
G01N33/53
PHYSICS
International classification
C12N15/10
CHEMISTRY; METALLURGY
Abstract
The present application provides a method of quantifying an amount of a derivatized peptide displayed on a phage by phage display, the method comprising: providing a phage containing a target peptide thereon; reacting the phage containing the target peptide with a first reagent to derivatize the target peptide to form a derivatized peptide, reacting the derivatized peptide with a capture agent comprising a detection marker, thereby incorporating the detection marker within the derivatized peptide; and determining an amount of the detection marker, thereby quantifying the amount of the derivatized peptide dis-played on the phage. A kit comprising a capture agent compris-ing a detection marker for quantifying the phage displayed derivatized peptides is also provided.
Claims
1. A method of quantifying derivatized peptides displayed on a phage by phage display, the method comprising: providing a phage containing a target peptide displayed thereon; reacting the phage containing the target peptide with a first chemical reagent to derivatize the peptide to form a derivatized peptide, reacting the derivatized peptide with a capture agent comprising a detection marker, thereby incorporating the detection marker within the derivatized peptide; and determining an amount of the detection marker, thereby quantifying the amount of the derivatized peptide displayed on the phage; reacting the derivatized peptide with a second reagent in a second reaction which eliminates the detection marker, and determining an amount of the detection marker after the second reaction, thereby quantifying the amount of the derivatized peptide after the second reaction.
2. The method of claim 1, wherein the detection marker is biotin, fluorescein or mannose.
3. The method of claim 1, wherein the target peptide is a peptide comprising an N-terminal amino acid.
4. The method of claim 3, wherein the N-terminal amino acid is serine, threonine or cysteine.
5. The method of claim 1, wherein the derivatized peptide is a glycopeptide or a macrocyclic peptide.
6. The method of claim 1, wherein the first reagent is NaIO4, iodoacetamide, or (tricarboxyethyl)phosphine (iTCEP).
7. The method of claim 6, wherein the concentration of NaIO4 is 20-500 μM.
8. The method of claim 7, wherein the concentration of NaIO4 is 20 or 500 μM.
9. The method of claim 1, wherein the capture agent is biotin-iodoacetamide (BIA), biotin-ARP, mannose-hydroxylamine, or chloroacetamide.
10. The method of claim 9, wherein the reaction time of the capture agent with the derivatized peptide is 1-4 hours.
11. The method of claim 4 wherein the target peptide is oxidized to form a derivatized peptide comprising an aldehyde group.
12. A method of quantifying derivatized peptide displayed on a phage by phage display comprising the steps of: providing a phage containing a target peptide displayed thereon; in a first reaction, reacting the phage containing the target peptide with a first chemical reagent to derivatize the peptide to form a first derivatized peptide having a first functional group (F1), in a second reaction, reacting the first derivatized peptide with a first capture agent (CA1) to react F1 to a second functional group (F2), wherein the first capture agent is coupled to a first detection marker, reacting the derivatized peptides with a second capture agent (CA2) coupled to a second detection marker, wherein CA2 is reactive with F1 and the second detection marker is different from the first detection marker, determining an amount of the first detection marker to quantify the amount of the derivatized peptide bearing F2, and determining an amount of the second detection marker to quantify the amount of derivatized peptide bearing F1; wherein the first chemical reagent oxidizes an N-terminal amino acid to produce an aldehyde moiety, and the second reagent converts the aldehyde moiety to an oxime.
13. The method of claim 12 wherein the first chemical reagent reduces disulfide bonds and CA1 alkylates the peptides.
14. A method of selecting for a first genetically encoded library of first derivatized peptides displayed on a phage (A) or a second genetically encoded library of second derivatized peptides displayed on a phage (B), comprising the steps of: providing phages containing a target peptide displayed thereon; producing a library of intermediate derivatized peptides from the target peptides with a chemical reagent; reacting the intermediate derivatized peptides with a capture agent coupled with a detection marker in a reaction which, if complete, results in the first derivatized peptides displaying the detection marker, and if incomplete, results in the second derivatized peptides not displaying the detection marker, isolating the first derivatized peptides using the detection marker; wherein the capture agent coupled with a detection marker comprises .sup.−C≡N.sup.+—biotin, which reacts with the aldehyde moiety to produce a macrocylic peptide, if complete.
15. The method of claim 14 wherein the target peptides are reacted to produce intermediate derivatized peptides having terminal aldehyde moieties.
Description
BRIEF DESCRIPTION OF THE FIGURES
(1) For a better understanding of the present invention, as well as other aspects and further features thereof, reference is made to the following description which is to be used in conjunction with the accompanying drawings, where:
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
DETAILED DESCRIPTION
Definitions
(20) Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
(21) As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.
(22) The term “comprising” as used herein will be understood to mean that the list following is non-exhaustive and may or may not include any other additional suitable items, for example one or more further feature(s), component(s) and/or ingredient(s) as appropriate.
(23) The term “assay” is used herein to refer to a test to qualitatively or quantitatively detect the presence of a substance in a sample.
(24) The term “biological sample” is used herein to refer to both animal and human body fluids, excreta and tissues obtained from a living or dead organism. The term “body fluid”, as used herein includes a naturally occurring and/or secreted and/or excreted and/or discharged fluid and/or wash fluid from the surface or inside the bodies of a human or an animal and includes, but is not limited to: saliva, sputum, serum, plasma, blood, pharyngeal, nasal/nasal pharyngeal and sinus secretions, urine, mucous, feces, chyme, vomit, gastric juices, pancreatic juices, semen/sperm, cerebral spinal fluid, products of lactation or menstruation, egg yolk, amniotic fluid, aqueous humour, vitreous humour, cervical secretions, vaginal fluid/secretions, bone marrow aspirates, pleural fluid, sweat, pus, tears, lymph and bronchial or lung lavage.
(25) The terms “body tissue” or “tissue”, as used herein, refer to an aggregate of cells usually of a particular kind together with their intercellular substance that form one of the structural materials of a plant or an animal and that in animals include, for example, connective tissue, epithelium, mucosal membrane, muscle tissue, placental tissue, and tissue from liver, intestines, spleen, kidney, brain, heart, nerve tissue, and the like. Samples of body tissue can be obtained from living humans or animals by a variety of non-limiting methods, such as fine needle aspirates, scrapings or biopsy tissue or from the remains of dead humans or animals. The term “tissue” can be used to refer to naturally occurring tissue or synthetic tissue.
(26) Biological samples can also include pre-processed foodstuffs including plants, samples of meats and processed foods, as well as swab samples from environmental sources such as food processing facilities, hospitals, water, soil, and air. Other biological sample types include isolates/fractions/concentrates of blood (e.g. platelets, red blood cells, white blood cells or leukocytes), including umbilical cord blood or placental blood, bone marrow, aspirates, fine needle organ or lesion aspirates, cervical samples, cultured cells, body swabs, or body smears.
(27) The terms “dormant bacteriophage” and “dormant phage” are used interchangeably to refer to bacteriophage that is non-infective, but that will become infective following activation.
(28) As used herein, the term “reporter gene” refers to a construct comprising a coding sequence attached to heterologous promoter or enhancer elements and whose expression product can be assayed easily and quantifiably when the construct is introduced into bacteria, for example through infection by bacteriophage carrying the reporter gene.
(29) As used herein, a “target peptide” is a peptide of interest displayed on the surface of phage that is to be derivatized and assayed. As would be understood, the surface of a phage can display a plurality of peptides; a target peptide, thus, is one of the plurality of displayed peptides which is targeted for derivatization and assaying.
(30) The term “capture agent” as used herein refers to a compound that reacts with a particular functional group on a phage-displayed peptide. The capture agent comprises a reactive moiety that reacts with the desired functional group, and a detection marker which is used to quantify the binding of the capture agent with the peptide. “Detection marker”, thus, refers to a molecule in association with the moiety to form the capture agent, and that is capable of being assayed when the capture agent reacts with and is attached to the desired functional group. Exemplary capture agents include those comprising reactive moieties that react with terminal aldehyde groups on the phage-displayed peptides, for example. Exemplary detection markers include biotin, fluorescein and mannose.
(31) As used herein, “derivatization” in the context of a “derivatized phage molecule” or “derivatized peptide” refers to the modification of a target peptide residue presented on the surface of a phage, prior to reaction with a capture agent. The modification typically involves reaction of a particular functional group presented on the target peptide, such as the terminal peptide residue, thus forming a derivatized phage molecule, such as a derivatized peptide. This derivatized peptide is then detected by and reacted with the capture agent.
Phage Display Quantification Process
(32) The quantification process as described herein generally employs two types of phage: peptide-displaying phage “P” and control peptide-free phage “C”. P contains an insert in its genome which encodes and displays a peptide with its coat proteins. P can also represent a library of sequences (P.sub.lib). The present method is designed such that no change in procedure is necessary when characterizing reaction on one phage P or a library of phage P.sub.lib.
(33) The control phage C is typically genetically similar to P, but lacks inserts in the phage genome and, thus, a lack of DNA sequence encoding peptides in the coat protein region. It is desired to be able to perform independent quantification of number of P and C phage particles in the same solution.
(34) Methods known in the art can be used to differentiate P and C phages. For example:
(35) i) P containing LacZ, while C is LacZ-free. The plaques corresponding to P and C are distinguishable by color on plates containing colorimetric reagent X-gal. Any suitable enzyme other than LacZ can be used, and visualized using known means, such as with a fluorescence substrate.
(36) ii) P containing genes encoding GFP, RFP or other fluorescent reporters in the genome, while C is reporter-free. The reporter does not have to be physically linked to any proteins of the phage; it simply can only be expressed in the host cell. The plaques corresponding to P and C can be distinguished by color or fluorescence on plates as described previously.
(37) iii) P containing antibiotic resistance gene in the phage genome, while C is resistance-free. The plaques corresponding to P and C can be distinguished by plating the mixture of phage on two plates, with and without the antibiotic. Alternatively, P and C can carry resistance for two types of antibiotics and visualized separately.
(38) iv) P comprises a sequence encoding a short peptide sequence such as FLAG recognized by a specific ligand, such as anti-FLAG antibody, while C is sequence-free. P and C phage can be distinguished by transferring the colonies onto nitrocellulose paper and probing with the antibody or other ligand.
(39) v) A mixture of P and C can be lysed to isolate DNA and subject to quantification of specific DNA sequence by real-time PCR or other quantitative methods. Primers for PCR are designed for insert region would recognize DNA of only P but not C.
(40) The characterization of the mixture of P and C is beneficial for determining the success of the phage display process. Alternatively, P and C can be modified chemically and quantified in two separate solutions. For simplicity, in all subsequent discussions, examples of the present method as described herein are based on the presence of reporter Xgal in P but not in C. This method allows for rapid quantification of P and C by counting plaques of specific color (blue for P and white for C) in a plaque-forming assay.
Analysis and Quantification of Phage Displayed Peptide Derivatives
(41) Characterization of phage libraries can be a challenge, because each library member is often present in mixture as a single molecule (single clone). The present method allows for quantification of reaction yields in multi-step reactions on complex mixtures of clones (for example, up to 10.sup.9 different peptides) using a series of capture agents for each reaction step. The method as described herein employs any known substrate molecule and detection technology that can be conducted on amino-acid sequences.
(42) Quantification and characterization of the chemical reactions in peptide libraries has been lacking. Existing approaches for quantitative characterization by spectroscopic methods (mass-spectrometry, elemental analysis) and biochemical methods (gel electrophoresis, Western blot, etc) are typically only applicable to large clonal population or phage and viruses (e.g., 10.sup.10-10.sup.13 particles). They cannot detect modifications which occur in a population that contains millions of different phage clones, with each clone present in low amount (e.g., 1-100 copies), The present method provides optimized reaction conditions for assaying derivatized peptide libraries.
(43) The present method can also be used for the improvement of yield in chemical reactions conducted on derivatized peptide libraries. In a collection of many peptides, certain peptides undergo a specific type of the reaction faster than others. For example, cyclization can occur faster in peptides of specific conformation, while substitution or elimination can occur in peptides of specific steric and electronic properties. Although the selection of individual peptide sequences with unique reactivity has been described previously (Barbas, et al., U.S. patent application Ser. No. 08/573,415, filed Dec 15, 1995; Eldridge, G. M., Weiss, G. A. (2011), Hydrazide reactive peptide tags for site-specific protein labeling. Bioconjugate Chem. 22: 2143-2153), the present invention allows for the optimization of multi-step reactions on peptides to generate a large library (10.sup.3-10.sup.8) of non-peptidic structures in high yield. Although these libraries are non-peptidic in nature, they are amplifiable quantitatively just like parent peptides. Their identities are genetically-encoded and can be deduced from the original peptidic starting materials.
(44) One advantage of the present method is serial optimization of the two-step modification of phage libraries. In one example, quantification of oxidation of N-terminal serine (Ser) and threonine (Thr) electrophilic addition to aldehyde is performed. In another example, quantification of site-selective reduction or disulphide and its alkylation by light-sensitive linker is shown. However, it would be understood that other functional groups, on other amino acids, whether terminal or internal within the displayed peptide, may be contemplated. The examples shown herein illustrate only certain embodiments of the present method.
(45) A library of phage-displayed peptide-derivatives generated with the help of a quantification approach contains a well-defined number of ligands of defined structure. In standard phage display, rounds of panning and amplification discover new peptides; in a library of peptide-derivatives rounds of modification, panning and amplification discover new peptide-derivatives.
(46) To illustrate the above described system and method, an exemplary panning of peptide-derivatives is shown on model proteins targets, such as streptavidin (for binding to biotin) and Concanavalin A (for binding to mannose). However, as would be readily understood that other protein targets using other capture agents and detection markers can be used.
(47) The phage concentrations [P].sub.0, [C].sub.0, [P].sub.b4, [C].sub.b4, [P].sub.af and [C].sub.af measured in the present method provide information about yield and specificity of the reaction (initial step 1), as well as its interference with viability of phage. Serial variation of the reaction conditions can be then performed to identify the best outcome in those parameters.
(48) The present method can be applied to other multi-step reactions. For example, multi-step reactions (Rxn1, Rxn2, etc.) can employ different reaction conditions. Rxn2 converts functional group F1 from Rxn1 to another functional group F2. To characterize Rxn2, a mixture of phage from reaction 1 is exposed to appropriate reagents (Reag2. 1 Reag 2.2, etc). After an appropriate time, the reaction is terminated and the yield concentration of group F2 is determined using capture agent 2 (CA2), which contains a group reactive with F2. Exposure to capture agent CA1, reactive to original group F1, can be used to quantify the amount of unreacted groups F1. For example, quantification of the reaction of aldehyde with hydroxylamine can be done by counting phage with unreacted aldehyde groups, using aldehyde reactive capture agent. Further, quantification of the reaction of thiols (quantification of unreacted thiols) can be done using thiol-specific capture agent. Also, quantification of the cyclization can be done using chloroacetamide reactive capture agent. Examples of these reactions are described herein.
(49) Thus, quantification and optimization of a N-step reaction can be done using N capture agents to quantify the yield at each step. Changing the condition at each step optimizes the yield at each step.
(50) The capture agents (CA1, CA2, etc., described above for quantification) can serve another purpose. They can be used to select members of the library that are prone to undergo a particular reaction more effectively. This selection can be applied when reactions are conducted on mixture of phage that display library of peptides P.sup.lib. By running reaction on P.sup.lib and C in specific conditions, the yield can be quantified using capture agent CA1. Unreacted peptides can be separated from those that are reacted. A sub-library containing derivatized peptides can be amplified to give a pure subpopulation of phage that contain modified ligands only. The present method provides several examples of this, including: (1) modification of a random library to select a sub-library with N-amino acids reactive to oxidation; and (2) modification of a random library of 7 amino acids flanked by two cysteines to select sub-library that can undergo efficient cyclization with unnatural linker.
Calculations of Yield and Viability
(51) Yield of the specific reaction is determined as: Y.sup.s=100%*[P].sub.af/[P].sub.b4
(52) Yield of the non-specific reaction is determined as: Y.sup.n=100%*[C].sub.af/[C].sub.b4.
(53) Yield of the reaction that occurs specifically on a peptide, as opposed to any other protein segment of the phage, is determined by comparing Y.sup.s and Y.sup.n. Ideally, the Y.sup.n is zero, while Y.sup.s is close to 100%.
(54) The viability of the phage over the course of the reaction is determined as V=100%*[P].sub.b4/[P].sub.0. Ideally, the viability of the reaction should be maintained close to 100%, and optimization of the length of reaction, and concentration of reagents, or their presentation can be used to maximize V. This can result in an increase of the yield with a decrease in viability, as shown herein (see, for example, in
(55) The ability to quantify the yield allows for rapid selection of optimal reaction conditions, which maximizes yield and specificity and minimizes interference with viability. Parameters that can be varied to optimize the yield and specificity include: reagent concentration and reaction time, and the presence of a catalyst. These parameters are exemplified herein.
(56) To gain a better understanding of the invention described herein, the following examples are set forth. It should be understood that these examples are for illustrative purposes only. Therefore, they should not limit the scope of this invention in any way.
EXAMPLES
Example 1: Two-Step Modification of Phage Libraries
(57) The synthesis of peptide derivatives is a sequence of reactions (for example, labelled “Rxn1”, “Rxn2”, etc.). In reaction 1, a mixture of peptide-displaying phage [P] and control peptide-free phage [C] in known concentration [P].sub.0 and [C].sub.0 are mixed with appropriate reagents (“Reag 1.1”, “Reag 1.2”, etc). After an appropriate time, the reaction is terminated and a capture agent 1 (CA1) is added. The capture agent typically contains a complimentary reactive group and, for example, biotin. The solution is then mixed with capture support (such as a magnetic bead with a biotin-binding protein streptavidin). Phage that has undergone the Rxn1 successfully is captured on the support. The numbers of phage before capture ([P].sub.b4 and [C].sub.b4) and after capture ([P].sub.af and [C].sub.af) are recorded.
(58)
(59)
(60)
(61) The concentration of biotin-ARP was also optimized to avoid non-specific binding. Ideally, the concentration of biotin-ARP is about 0.2-5 mM, typically 0.2 mM, 1 mM or 5 mM. The ideal reaction time (Rxn 2) was found to be 1-4 hours, typically 1, 2, 3 or 4 hours incubation time. The addition of an analine catalyst was found to favourably promote the reactions.
(62)
(63) In
(64)
(65)
(66)
Example 2: Optimization of Cysteine (Cys)-Containing Residues
(67)
(68)
(69)
Example 3: Cyclization Reaction
(70) Exemplified herein is the generation of large sub-libraries, from random peptide libraries, that undergo quantitative N-terminal oxidation, and an efficient three-step cyclization via nucleophilic substitution, cyclization and rearrangement through the Ugi reaction.
(71) A selection for sub-library of sequences that can undergo complex, multi-component reactions involving multiple natural side chains. As an example, the Ugi multi-component reaction was performed. This reaction requires amine, carboxylic acid, aldehyde and isocyanide (see
(72)
(73)
(74)
(75)
Example 4: Comparison of Present Method with Other Biochemical Methods
(76)
(77)
(78) Thus, it can be seen that the present method offers improved detection and quantification of derivatized peptides over conventional bulk methods.
Example 5: Optimization of the Capture of Derivatized Peptides by Biotin/Streptavidin Interactions
(79)
Example 6: Optimization of Various Aldehyde Reactions on Phage
(80)
(81)
(82) All publications, patents and patent applications mentioned in this Specification are indicative of the level of skill of those skilled in the art to which this invention pertains and are herein incorporated by reference to the same extent as if each individual publication, patent, or patent applications was specifically and individually indicated to be incorporated by reference.
(83) The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.